Transgender Women At High Risk Of Cervical Cancer- Study

A new study has revealed that Transgender women receiving hormonal therapy are at greater risk of developing breast cancer.

The study dubbed “Breast Cancer Risk in transgender people receiving hormone treatment” has revealed that there was an increased risk of breast cancer in trans women compared with cisgender men, and a lower risk in trans men compared with cisgender women. In trans women, the risk of breast cancer increased during a relatively short duration of hormone treatment and the characteristics of the breast cancer resembled a more female pattern.

Most trans women were treated with a combination of antiandrogens and oestrogens. Antiandrogen treatment usually consisted of cyproterone acetate (a progestogenic antiandrogen, 10 to 100 mg daily) or spironolactone (100 to 200 mg daily), and treatment was often stopped after orchiectomy.

“Oestrogen was prescribed as ethinylestradiol (25 to 100 µg daily), conjugated oestrogens (0.625 to 1.25 mg daily), estradiol patches (50 to 150 µg/24 hours twice weekly), estradiol implants (20 mg every 3 to 6 months), estradiol injections (10 to 100 mg every 2 to 4 weeks), estradiol valerate (2 to 6 mg daily), or estradiol gel (0.75 to 3.0 mg daily),” said the study.

Trans men were treated with either testosterone gel (20 to 100 mg daily), intramuscular testosterone esters (150 to 250 mg every 2 to 3 weeks), or oral or intramuscular testosterone undecanoate (orally: 40 to 160 mg daily, intramuscularly: 1000 mg every 10 to 14 weeks).

Trans men who experienced persistent menstrual blood loss during testosterone treatment were in some cases treated with additional progestogens such as lynestrenol (5 to 10 mg daily). People who started hormone treatment younger than 18 years often received only gonadotrophin releasing hormone agonists before the addition of oestrogen or testosterone treatment.


Related posts

Leave a Comment